Advertisement

---

ZAFGEN, INC.

Zafgen Announces New Body Weight Loss and Cardiometabolic Data from Phase 2 Study of Beloranib in Obesity at American Diabetes Association's 73rd Scientific Sessions®

[2013-06-22] - Interim Results Show Treatment with Beloranib Resulted in Clinically Meaningful Body Weight Loss and Improvements in Multiple Cardiometabolic Risk Factors in Severely Obese Subjects


Advertisement
Most read: scientific news

More:

---


---
Follow us...

google plus Facebook twitter Newsletter

---


---

Plan du site

Actualités

Actualités

Actualités

Réglementaire

Emploi

Annuaires

Dictionnaire

Divers